If you are part of the health policy community you might want to check out a new book, Building Better Pharma Policy in Canada. The book examines the unintended consequences, opportunity costs, and the impact on patients, taxpayers, innovation, and trade relations – caused by

CHPI E-news mid summer research update: https://t.co/7WSRkThpQc

The plan was clean. The escape? Not so much. Midway City doesn’t play fair. Wishlist this 4-player coop heist FPS on Steam today.

Opinion: National pharmacare will reduce drug access for almost 26 million Canadians 

Opinion: National pharmacare will reduce drug access for almost 26 million Canadians 

National pharmacare will reduce access to new medicines for 27 million privately insured Canadians

Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients

Opinion: Controlling drug costs doesn't require pharmacare

Cost control rationale for pharmacare does not stand up to scrutiny: Canadian Health Policy Institute https://t.co/PpZkyoQfP7

National pharmacare is not necessary. It will be bad for patient access and costly for taxpayers. In this Toronto Star opinion CHPI CEO Brett Skinner identifies several inconvenient facts, ignored by pharmacare advocates: - People in the lowest income deciles who fall in the gaps

Dr. Nigel Rawson in the Hill Times: The Patented Medicine Prices Review Board (PMPRB) has demonstrated such dysfunction and bias it should be disbanded. https://t.co/2EQT7IT6IW

NEW STUDY - Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021. Nigel SB Rawson, PhD and Brett J Skinner, PhD. #healthpolicy #cdnpoli https://t.co/oNh99dIFmj

CHPI's Yanick Labrie co-authored a new study suggesting that Quebec could save over $7 million annually if patients with HER2+ breast cancer received subcutaneous administration of Herceptin® at local community service centres (CLSCs) rather than receiving it intravenously in

Cancer is the leading cause of death in Canada, but public drug plans cover only 11% of new cancer drugs, Canadians wait 1,835 days for coverage, and sales of new cancer drugs are only 1.3% of national health expenditure: new study. #cdnpoli #cdnecon https://t.co/oNh99dIFmj

New study: Economic burden of cardiomyopathy $5 billion/yr. Patented drugs account for less than 1%. As first line therapy pharmaceutical innovation offers opportunity to avoid downstream hospital cost, productivity loss, mortality. #cdnhealth #cdnpoli https://t.co/oNh99dIFmj

Cancer is the leading cause of death in Canada, but public drug plans cover only 11% of new cancer drugs, Canadians wait 1,835 days for coverage, and sales of new cancer drugs are only 1.3% of national health expenditure: new study. #cdnpoli #cdnecon https://t.co/oNh99dIFmj

New study: Economic burden of cardiomyopathy $5 billion/yr. Patented drugs account for less than 1%. As first line therapy pharmaceutical innovation offers opportunity to avoid downstream hospital cost, productivity loss, mortality. #cdnhealth #cdnpoli https://t.co/oNh99dIFmj

"the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency – has sought to impose lower drug costs when new pharmaceuticals are introduced here. But the main achievement of that crusade is that fewer new medicines are now

Is it time to retire the patented medicines price regulator? Recommended read from CHPI's Nigel Rawson and John Adams in the Financial Post: https://t.co/SkSiU8dsrU. #pmprb #cdnhealth #cdnpoli

Read the latest article from CHPI's Nigel Rawson and John Adams... Opinion: For drug access, Canadians with rare disorders are 40 years behind Americans https://t.co/XydfdVxHee #Pharmaceutical #Health #Canada #PMPRB